Clinical trials: Mood Disorder
- Condition Mood Disorder
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Major Depressive Disorder
IM and IV SPL026 Drug Product in Healthy Participants
The goal of this clinical trial is to test SPL026 given via injection into a muscle in healthy volunteers.
- Trial name
- NCT05644093
- Testing
- SPL026 IV, SPL026 IM
- Where
- United Kingdom
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Small Pharma Ltd
Metabolic Syndrome, Anxiety
PRebiotic Intervention for Metabolic and MEntal Health (PRIME)
The purpose of the study is to determine whether a daily prebiotic fibre blend can reduce systemic inflammation, dyslipidemia, and self-report measures of mental health in individuals with metabolic syndrome.
- Conditions
- Metabolic Syndrome, Anxiety, Mood, Stress
- Trial name
- PRIME (NCT06216626)
- Testing
- myota's prebiotic fibre blend
- Where
- United Kingdom
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Myota GmbH
Anxiety Disorders, Major Depressive Disorder
Acquisition and Analysis of Relationships Between Longitudinal Emotional Signals Produced by an Artificial Intelligence Algorithm and Self-questionnaires Used in the Psychiatric Follow-up of Patients With Mood and/or Anxiety Disorders: a Real-Environment Study.
The worldwide prevalence of anxiety and depression increased massively during the pandemic, with a 25% rise in the number of patients suffering from psychological distress.
- Trial name
- EMOACQ-1 (NCT05988840)
- Testing
- Acquisition and analysis of relationships between Longitudinal Emotional Signals produced by a software and Self-questionnaires.
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Emobot
Depression, Anxiety
Pharmacogenomic Testing to Optimize Antidepressant Drug Therapy
A randomized controlled trial comparing pharmacogenomic guided versus standard pharmacist care to optimize antidepressant drug therapy.
- Conditions
- Depression, Anxiety, Major Depressive Disorder, Generalized Anxiety Disorder
- Trial name
- NCT03591224
- Testing
- Pharmacogenomic Testing, Pharmacist Standard of Care
- Where
- 2 sites in Canada
- Volunteers
- 213 people, healthy volunteers welcome
- Sponsor
- John Papastergiou Pharmacy Ltd
Major Depressive Disorder
Effect of Food, Gender, and Age on the Pharmacokinetic Profile of SUVN-911 in Healthy Subjects
The purpose of the study is to investigate the effect of Food, Gender, and Age on the Pharmacokinetic Profile of SUVN-911 in Healthy Subjects
- Trial name
- SUVN-911 (NCT03551288)
- Testing
- SUVN-911
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Suven Life Sciences Limited
PTSD, Alzheimer Disease
First-In-Human (FIH), Single Ascending Dose (SAD) Study of FluoroEthylNorMemantine (FENM)
The goal of this First-In-Human (FIH) trial is to learn about safety and PharmacoKinetics (PK) in healthy adult volunteers. The main questions it aims to answer are: What is the safety of single ascending doses of the…
- Conditions
- PTSD, Alzheimer Disease, Brain Diseases, Neuro-Degenerative Disease
- Trial name
- NCT05921929
- Testing
- Fluoroethylnormemantine (FENM)
- Where
- Belgium
- Volunteers
- healthy volunteers welcome
- Sponsor
- ReST Therapeutics
PostPartum Depression
Curio Digital Therapy for the Treatment of Post-partum Depression
Primary Objective: Evaluate the clinical effectiveness of the MamaLift Plus app compared to control (digital sham plus treatment as usual) for the management of PPD in the observed population for a period of 9 calendar weeks.
- Trial name
- SuMMER (NCT05958095)
- Testing
- MamaLift Plus
- Where
- United States
- Volunteers
- 142 people, healthy volunteers welcome
- Sponsor
- Healthcare Innovation Technology Lab
Major Depressive Disorder
A Study of LY2216684 and Theophylline in Healthy Subjects
The primary objective of this study is to confirm that LY2216684 is not an inhibitor of cytochrome P450 1A2 (CYP1A2) in healthy participants using theophylline as a probe substrate for the enzyme.
- Trial name
- NCT01263106
- Testing
- LY2216684, Theophylline
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Depressive Disorder, Major, Diabetic Neuropathies
Study Evaluating the Potential of DVS SR to Inhibit the CYP2D6 Pathway
To evaluate the effects of multiple oral doses of desvenlafaxine sustained release (DVS SR) and paroxetine on the biotransformation of codeine to morphine in healthy subjects.
- Conditions
- Depressive Disorder, Major, Diabetic Neuropathies, Fibromyalgia, Vasomotor Symptoms
- Trial name
- NCT00456898
- Testing
- desvenlafaxine sustained release (DVS SR), Paroxetine, Codeine
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Major Depressive Disorder
Study Evaluating the Effect of Desvenlafaxine on the Pharmacokinetics of Midazolam
The main purpose of this study is to evaluate the effect of desvenlafaxine administered as DVS SR on the pharmacokinetics of midazolam in healthy male and female subjects.
- Trial name
- NCT00952653
- Testing
- Desvenlafaxine Succinate Sustained Release, Midazolam
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Pfizer
Fatigue, Low Mood
A Study to Evaluate the Effects of a Beef Liver Supplement on Energy, Mood, and Mental Clarity
This is a randomized, triple-blind, placebo-controlled clinical trial evaluating the effects of the Ancestral Supplements Grass Fed Beef Liver oral supplement on energy, mood, and mental clarity over 12 weeks.
- Conditions
- Fatigue, Low Mood, Mental Clarity, Iron Deficiency
- Trial name
- NCT07892911
- Testing
- Intervention
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Ancestral Supplements, LLC
Schizophrenia
A Study of the Effect of Food and Posture on the Pharmacokinetics of a Single Dose of ER OROS Paliperidone
The purposes of this study are to evaluate the effect of food on the pharmacokinetics of extended-release (ER) OROS paliperidone in healthy men, and to evaluate the effect of posture on the pharmacokinetics of ER OROS…
- Trial name
- NCT00838669
- Testing
- Extended release OROS paliperidone
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Anxiety, Depression
Ginger.io Behavioral Health Study
This Study will evaluate the impact of a smartphone-based platform on a range of outcomes for medically-underserved patients with mood disorders (e.g.
- Conditions
- Anxiety, Depression, Bipolar I Disorder, Bipolar II Disorder
- Trial name
- NCT02491307
- Testing
- Ginger.io Smartphone Application
- Where
- 4 sites in United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Community Health Center, Inc.
Major Depressive Disorder (MDD)
A Study to Assess the Skin Irritation and Sensitization of Selegiline TDS in Healthy Subjects
The two products used in this study are transdermal patches that contain selegiline. The test drug is the Selegiline Transdermal Delivery System (TDS). The comparator drug is the EMSAM® TDS.
- Trial name
- NCT07452692
- Testing
- Selegiline Transdermal Delivery System
- Where
- 3 sites in Bulgaria
- Volunteers
- 232 people, healthy volunteers welcome
- Sponsor
- Corium Innovations, Inc.
Healthy
Study Evaluating the Pharmacokinetics of Venlafaxine ER and Desvenlafaxine SR in Healthy Subjects
The purpose of this study is to determine if the relative difference in PK between extensive metabolizers (EMs) and poor metabolizers (PMs) is the same with desvenlafaxine SR and venlafaxine ER when a single dose is administered.
- Trial name
- NCT00329186
- Testing
- desvenlafaxine SR, venlafaxine ER
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Depressive Disorder
28-day Repeat Dose and Drug Interaction Study With Orvepitant (GW823296)
This study is being conducted to obtain information on the safety and tolerability of repeated doses of GW823296 for 28 days in healthy male and female subjects.
- Trial name
- NCT00511654
- Testing
- GW823296 tablet, Midazolam
- Where
- Germany
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Treatment Resistant Depression
Linear Asymmetric rTMS in Adolescent Treatment-Resistant Depression: Tolerability of Treatment Durations Ranging From Ten Days to One Day
This is a pilot interventional study to investigate the acceptability, tolerability, and side effect profile for varying numbers of treatment sessions/day of a new rTMS treatment in adolescents with treatment-resistant depression…
- Trial name
- NCT03986658
- Testing
- Linear Asymmetric rTMS System
- Where
- Canada
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- NeuroQore Inc.
Pregnancy Related, Mental Health Issue
MamaConecta: Digital Tool for Maternal Mental Health
The goal of this randomized controlled trial is to validate a digital health tool, Dana app, that enhances well-being and supports mental health monitoring for women during the perinatal period.
- Conditions
- Pregnancy Related, Mental Health Issue, Postpartum Depression, Postpartum Anxiety
- Trial name
- DDT (NCT06442774)
- Testing
- Mobile application, Monitoring via wearable
- Where
- 3 sites in Spain
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- A Thousand Colibris, S.L
Major Depressive Disorder
the Safety, Tolerability, and Pharmacokinetics Study of HEC113995
Multiple Dose Safety, Tolerability, PK and Food Effect Study of HEC113995 PA•H2O in Healthy Subjects
- Trial name
- NCT04623814
- Testing
- Food, HEC113995
- Where
- China
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Depressive Disorder, Major
Study to Evaluate the Performance Validity and Test-Retest Reliability of a Computer-Administered Cognitive Test Battery in Participants With Major Depressive Disorder (MDD)
The purpose of this study is to examine concurrent validity of 8 computerized tests intended for the assessment of cognitive function in participants with Major Depressive Disorder (MDD), relative to 8 corresponding and…
- Trial name
- NCT03014544
- Testing
- Computer- administered test battery, Examiner- administered test battery
- Where
- 20 sites in United States
- Volunteers
- 585 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC